An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

The FDA and Novo Nordisk are warning of counterfeit Ozempic® (semaglutide) which could pose a safety risk. The FDA and ...

Unlike the array of new injectable GLP-1 drugs, there is only one oral GLP-1 medicine that is currently on the market: Novo Nordisk’s Rybelsus. This semaglutide pill mimics the gut hormone GLP-1 ...

The injectable forms of semaglutide — Ozempic for diabetes and Wegovy for weight loss — have solid evidence backing up their claims of cardiovascular protection. The oral form, marketed as ...

an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers reported at the American College of Cardiology scientific ...

Both injectable and oral forms of semaglutide are already approved by the U.S. Food and Drug Administration but the oral formulation’s impact on cardiovascular outcomes has not previously been ...

In the randomized STRIDE trial, a year of semaglutide (Ozempic, Wegovy) injections increased the walking ability of people with type 2 diabetes (T2D) and lower limb PAD by 21%, a significant ...

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...

“Semaglutide originally came to market as a once-weekly injectable where it's now approved for use for the treatment of hyperglycemia and to reduce cardiovascular risk in people with type two diabetes ...